FDA
Stories
-
FDA approves giredestrant with everolimus for ESR1-mutated breast cancer
On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.
-
FDA draft guidance sets out how early-phase solid tumor protocols should handle eligibility, dosing and consent
A November 2026 FDA draft guidance for sponsors and clinical investigators recommends eligibility, dose escalation, consent and sampling practices for first-in-human and other early-phase solid tumor trials. Comments are due January 11, 2027.
-
FDA approves first drug to treat adults with primary membranous nephropathy
The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.
-
FDA releases draft guidance on early-phase IND protocols for solid tumors
FDA announced the availability of a draft guidance titled "Early-Phase IND Protocol Recommendations for Solid Tumors" to provide recommendations for sponsors and investigators developing early-phase trials. Comments are due by January 11, 2027, and the guidance covers first-in-human protocols for drugs and biologic products with limited human experience, but does not address hematologic malignancies.
-
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.
-
FDA actions, week of November 9, 2026: 4 approvals, 1 rule, 1 notice
The FDA published 6 actions in the week of November 9 to 15, 2026: 4 approval announcements, 1 final rule in the Federal Register and 1 notice in the Federal Register.
-
FDA partially grants petition to remove methylene chloride as color additive diluent
The order removes a solvent used as a diluent in inks for marking fruit and vegetables, effective January 11, 2027. Requests to remove ethylene dichloride and trichloroethylene from extraction solvents for annatto, paprika, and turmeric were denied because residues would be impurities not covered by the Delaney Clause.
-
Johnson & Johnson FDA grants accelerated approval for RYBREVANT FASPRO in head and neck cancer
The FDA granted accelerated approval for RYBREVANT FASPRO as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval was based on the Phase 1b/2 OrigAMI-4 trial, in which the confirmed overall response rate was 42 percent per blinded independent central review.
-
FDA draft would require IDE applications for device trials to come in through eSTAR
An FDA draft guidance of October 28, 2026 would require IDE applications to be electronic submissions built in eSTAR, with no waivers and a transition of at least one year after the final guidance. Comments are due December 28, 2026.
-
FDA approves RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval to RYBREVANT FASPRO, a co-formulated amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.
-
FDA classifies external mechanical stimulator for congestion as class II
A final order has been issued to place the device for relieving congestion into category II, adding special controls. The action is intended to provide reasonable assurance of safety and effectiveness and to enhance patients' access to innovative devices by reducing regulatory burdens.
-
Johnson & Johnson announces FDA approval of RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval is based on a 42 percent overall response rate (95 percent CI, 32-52 percent) from the Phase 1b/2 OrigAMI-4 trial.